(Q43784459)

26 November 2017

title

Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis (English)

1 reference

26 November 2017

1 reference

J M McCarty

1

1 reference

26 November 2017

P F Pierce

series ordinal

2

1 reference

26 November 2017

publication date

1 October 2001

1 reference

Annals of Allergy, Asthma & Immunology

26 November 2017

published in

1 reference

26 November 2017

volume

87

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

327-334

1 reference

Infectious exacerbations of chronic bronchitis: diagnosis and management

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

The macrolides: erythromycin, clarithromycin, and azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

The role of antimicrobial therapy in acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Clinical efficacy of azithromycin in lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

Pneumococcal macrolide resistance--myth or reality?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962248-X

7 January 2021

10.1016/S1081-1206(10)62248-X

Identifiers

DOI

1 reference

26 November 2017

1 reference